AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology’s 71st Annual Scientific Session

21 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention

10 Mar 2022 08:47:44 By Nasdaq GlobeNewswire

Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

01 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Amarin to Participate in Cowen 42nd Annual Health Care Conference

25 Feb 2022 08:00:00 By Nasdaq GlobeNewswire

JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level

24 Feb 2022 07:30:01 By Nasdaq GlobeNewswire

Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022

15 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Amarin Provides Preliminary 2021 Revenue and Outlook for 2022

10 Jan 2022 07:00:04 By Nasdaq GlobeNewswire

Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021

16 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scientific Sessions 2021

15 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Amarin to Present at Two Upcoming Investor Conferences

11 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021

08 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update

03 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

20 Oct 2021 07:05:00 By Nasdaq GlobeNewswire

Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.

22 Sep 2021 09:15:00 By Nasdaq GlobeNewswire

Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany

13 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Amarin to Participate in September Investment Conferences

13 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology

31 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of Cardiology

23 Aug 2021 03:15:00 By Nasdaq GlobeNewswire

Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology

16 Aug 2021 07:00:01 By Nasdaq GlobeNewswire